Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 11/20 | 0.41 |
| ▸ | MAPT | P10636 | 10/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15076775 | 0.91 | LMNA (0.55) | HTR2BLMNAALDH1A1KMT2ATP53 | |
| SCHEMBL15076573 | 0.87 | HTR2B (0.53) | HTR2BLMNAALDH1A1KMT2ATP53 | |
| SCHEMBL15076821 | 0.84 | HTR2B (0.49) | HTR2BLMNAALDH1A1KMT2ATP53 | |
| SCHEMBL15276981 | 0.83 | HTR2B (0.51) | HTR2BLMNAALDH1A1KMT2ATP53 | |
| SCHEMBL15076774 | 0.82 | HTR2B (0.62) | HTR2BLMNAALDH1A1KMT2ATP53 | |
| SCHEMBL15076791 | 0.82 | LMNA (0.62) | HTR2BLMNAALDH1A1KMT2ATP53 | |
| SCHEMBL15076776 | 0.78 | HTR2B (0.58) | HTR2BLMNAALDH1A1KMT2ATP53 | |
| SCHEMBL15076809 | 0.78 | HTR2B (0.58) | HTR2BLMNAALDH1A1KMT2ATP53 | |
| SCHEMBL15612908 | 0.78 | HTR2B (0.75) | HTR2BLMNAALDH1A1KMT2ATP53 | |
| SCHEMBL21623153 | 0.76 | MAPT (0.68) | LMNATP53MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196376-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170334882-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196376-B2 | Hepatitis B antiviral agents | HAVCR2, EIF2AK2, IRF3 | HTR2B 4016/4885LMNA 3521/4885ALDH1A1 1564/4885 |
| US-20170334882-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | HTR2B 4016/4885LMNA 3521/4885ALDH1A1 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.